スポンサーサイト

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。


Cancer Topics Index 04/12/2016(Daily Test version/ 日刊テスト版)No.08

konpas.jpg
Cancer Topics Index 04/12/2016(Daily Test version/ 日刊テスト版) No.08

Flags 【海外:overseas】
◇NCI (National Cancer Institute)◇
【転移性乳がん/注射用ナノ粒子生成技術(iNPG)】
accumulation-inpg-pdox-metastatic-tumors-article.jpg
Nanoparticle Generator Slips Chemotherapy Past Tumor Cells’ Protective Barriers (April 11, 2016 by NCI Staff)
Researchers have developed and tested a new injectable nanoparticle-generating technology that can deliver doxorubicin (Adriamycin®), a commonly used chemotherapy drug, straight to the nucleus of metastatic breast cancer cells with high effectiveness.In the study, the treatment approach led to complete remissions in mice with a hard-to-treat form of breast cancer. The findings appeared in Nature Biotechnology on March 14. The research team that led the study hopes to start testing the treatment in human clinical trials by the end of 2017.

logo-clinicaltrials-gov.png
rinnsyo1.jpg
※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
15 studies found for: cancer | received from 03/29/2016 to 03/29/2016

【甲状腺未分化がん】
1 Recruiting
Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
Condition: Anaplastic Thyroid Cancer
Intervention: Drug: Lenvatinib
Sponsor:Translational Research Informatics Center, Kobe, Hyogo, Japan
ClinicalTrials.gov Identifier:NCT02726503

【トリプルネガティブ乳がん】
2 Not yet recruiting
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
Conditions: Breast Cancer; Metastatic Triple Negative
Interventions: Drug: Pembrolizumab; Radiation: Radiotherapy
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02730130

【胃がん/胃食道接合部がん】
3 Recruiting
Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer
Conditions: Gastric Cancer; Gastroesophageal Junction Cancer
Interventions: Drug: Ramucirumab; Drug: Trastuzumab; Drug: Capecitabine/Cisplatin
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02726399

【大腸がん】
4 Recruiting
Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease
Conditions: Inflammatory Bowel Disease; Colorectal Cancer
Intervention:
Sponsor:Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:NCT02726243

【前立腺がん】
5 Not yet recruiting
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsor:Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:NCT02726009

【肺がん】
6 Recruiting
Evaluate the Utility of the ProLung Test in the Diagnosis of Lung Cancer
Conditions: Solitary Pulmonary Nodule; Multiple Pulmonary Nodules
Intervention:
Sponsor:Chinese Alliance Against Lung Cancer
ClinicalTrials.gov Identifier:NCT02726633

【乳がん/リンパ浮腫】
7 Not yet recruiting
Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema
Conditions: Breast Cancer; Lymphedema
Interventions: Drug: Wuling San; Drug: placebo
Sponsor:Fourth Affiliated Hospital of Guangxi Medical University
ClinicalTrials.gov Identifier:NCT02726477

【未分化大細胞リンパ腫】
8 Not yet recruiting
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive; Systemic Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Ceritinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsor:University of Washington
ClinicalTrials.gov Identifier:NCT02729961

【甲状腺がん】
9 Recruiting
Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences
Condition: Thyroid Cancer
Intervention:
Sponsor:Mayo Clinic
ClinicalTrials.gov Identifier:NCT02726282

【頭頸部がん】
10 Not yet recruiting
Smartphone Pain App for Assessing Oral Mucositis Pain in Patients Receiving Head and Neck Radiation Therapy
Condition: Oral Mucositis
Intervention: Other: OM Pain App
Sponsor:Stuart Wong
ClinicalTrials.gov Identifier:NCT02727062

【慢性骨髄性白血病】
11 Not yet recruiting
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Other: Laboratory Biomarker Analysis; Drug: Pioglitazone Hydrochloride; Drug: Tyrosine Kinase Inhibitor (TKI)
Sponsor:Emory University
ClinicalTrials.gov Identifier:NCT02730195

【非小細胞肺がん】
12 Recruiting
High Dose Icotinib For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Conditions: Non-small Cell Lung Cancer; Brain Metastases
Interventions: Drug: Icotinib; Radiation: WBRT; Drug: chemotherapy
Sponsor:Betta Pharmaceuticals Co.,Ltd.
ClinicalTrials.gov Identifier:NCT02726568

【リンパ腫】
13 Recruiting
Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
Condition: Lymphoma
Intervention: Biological: CD19-targeted CAR-T cells
Sponsor:Sinobioway Cell Therapy Co., Ltd.
ClinicalTrials.gov Identifier:NCT02728882

◇EU, EMA, CHMP, Cancer Research UK, NICE◇
【代謝イメージングトライアル】
First cancer patient in Europe scanned in Cambridge using new technique showing whether drugs work (11 April 2016 Cancer Research UK)
The first cancer patient in Europe has been scanned with a revolutionary imaging technique that could enable doctors to see whether a drug is working within a day or two of starting treatment.The patient is the first to take part in a new metabolic imaging trial* of patients across a wide range of cancer types to be carried out by Cancer Research UK-funded scientists at Addenbrooke’s Hospital, part of Cambridge University Hospitals. The study, which is funded by a Wellcome Trust Strategic Award, could show whether patients can stop taking drugs that aren’t working for them, try different ones and receive the best treatment for their cancer as quickly as possible.

<Pharmaceuticals and Medical Devices>
【腎細胞がん】
European Commission Approves Bristol-Myers Squibb’s Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma (April 6, 2016 BMS)
欧州委員会、オプジーボ®(一般名:ニボルマブ)について治療歴を有する進行期腎細胞がんの適応を承認 (04/08/2016 ブリストル・マイヤーズ スクイブ Bristol-Myers Squibb/小野薬品工業 ONO PHARMACEUTICAL) pdf

<Medical Journal & Other News>
headline.jpg
【多形性膠芽腫/薬剤耐性の別ルート】JOURNAL:Cancer Cell
A different route to drug resistance (04/11/2016 EurekAlert!/LUDWIG INSTITUTE FOR CANCER RESEARCH)
April 11, 2016, NEW YORK - A team of researchers, led by Ludwig Cancer Research scientist Paul Mischel and James Heath of the California Institute of Technology, has probed biochemical signaling cascades within individual cancer cells to capture a previously poorly understood but clinically significant mechanism of cancer drug resistance. Published in the current issue of Cancer Cell, their paper shows that cells of the invariably lethal brain cancer glioblastoma multiforme (GBM) begin adapting to resist therapy within as little as three days of its initiation. The researchers further show that their technology and analytical approach has the potential to be harnessed by clinicians to anticipate, and even overcome, drug resistance to GBM.

【ホジキンリンパ腫/PETによる化学療法副作用の調整】JOURNAL:Journal of Clinical Oncology
PET scans guiding chemo boosts remission for Hodgkin patients (04/11/2016 EurekAlert!/SWOG)
PORTLAND, OR - Using PET imaging to guide chemotherapy treatment significantly increases the number of people who go into remission and also decreases toxic side effects for people with advanced Hodgkin lymphoma, according to research conducted by SWOG and two other National Cancer Institute research groups.

【樹状細胞におけるCTLA-4の発見と可能性】JOURNAL:Stem Cells and Development
Discovery of CTLA-4 in dendritic cells opens new possibilities to fight cancer (04/08/2016 EurekAlert!/BAYLOR COLLEGE OF MEDICINE)
T cells are the 'foot soldiers' that fight cancer inside the body. Cancer cells can fight the foot soldiers back by pushing a brake on the T cells that will turn them off. This 'brake' is a molecule on the surface of T cells called CTLA-4. Until now, most scientists agreed that CTLA-4 was only present on T cells and other cells of the same lineage. But Baylor College of Medicine researchers have discovered that CTLA-4 is also produced and secreted by dendritic cells, which are the 'generals' of the T cells in the battle against cancer. The results appear in Stem Cells and Development.

【ナノ粒子DDS】JOURNAL:Nano Letters
Dressed to kill: Tailoring a suit for tumor-penetrating cancer meds (04/08/2016 EurekAlert!/DREXEL UNIVERSITY)
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body. Tiny capsules, called nanoparticles, are now being used to transport chemotherapy medicine through the bloodstream, to the doorstep of cancerous tumors. But figuring out the best way for the particles to get past the tumor's "velvet rope" and enter the tumor is a challenge scientists are still working out. Drexel University researchers believe that the trick to gaining access to the pernicious cellular masses is to give the nanoparticles a new look -- and that dressing to impress will be able to get them past the tumor's biological bouncers.

【前立腺がん/アンドロゲン除去療法と併用される化学療法や放射線療のタイミング】JOURNAL:Science Translational Medicine
Common prostate cancer treatments suppress immune response and may promote relapse (04/07/2016 EurekAlert!/UT SOUTHWESTERN MEDICAL CENTER)
DALLAS - April 7, 2016 - Prostate cancer patients and their doctors may want to think twice about the best timing for chemotherapy or radiation therapy in conjunction with a common nonsurgical treatment, based on international research findings led by UT Southwestern Medical Center investigators.

【前立腺がん】
Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up.(PubMed/Eur Urol. 2016 Mar 28)
月21回以上の射精で前立腺がんリスク2割減―米調査 (04/11/2016 健康百科)

Graphics 【日本国内:Japan】
<Press Release:日本国内>
【肝臓がん】
肝臓がん300例の全ゲノムを解読-ゲノム構造異常や非コード領域の変異を多数同定- (04/11/2016 国立がん研究センター/AMED)
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer (Published online 11 April 2016 Nature Genetics)
日本人300例の肝臓がんの全ゲノムシーケンス解析を実施し、それらのゲノム情報を全て解読しました。この研究は、国際がんゲノムコンソーシアム(ICGC)のプロジェクトの一環として行われ、単独のがん種の全ゲノムシーケンス解析数としては世界最大規模となりました。これらのゲノム情報によって肝臓がんは6つに大きく分類され、肝臓がん術後生存率はこの分子分類によって異なることが分かりました。

◇PMDA(医薬品医療機器総合機構◇
◆承認情報(医療用医薬品)掲載のお知らせ (04/11/2016 PMDA)
・イムブルビカカプセル140mg 【承認】(平成28年3月承認分)
再発又は難治性の慢性リンパ性白血病(小リンパ球性リンパ腫を含む)を効能・効果とする
新有効成分含有医薬品
掲載ページ:http://www.pmda.go.jp/drugs/2016/P20160404001/navi.html

・ゾーフィゴ静注 【承認】(平成28年3月承認分)
骨転移のある去勢抵抗性前立腺癌を効能・効果とする新有効成分含有医薬品
掲載ページ:http://www.pmda.go.jp/drugs/2016/P20160407001/navi.html

<News>
トレンド・ボックス 早期発見へ、採血1回で13種類のがんを識別 国立がん研究センター、東レ、日本医療研究開発機構など (04/11/2016 日経ビジネス)

がんに対するPrecision Medicineについて (04/11/2016 ヘルスクリック)

Access Accepted第494回:医療現場で成果を発揮するゲーム (04/11/2016 4gamer.net)

乳がん闘病のサポートは“愛情よりもお金”で決まる (04/10/2016 PRESIDENTOnline)

<雑誌記事:Magazine/Medical journal>
Stockholm Public Library
◆Mebio (2016年5月号)/メジカルビュー社/発売日:2016年4月11日/価格(税込):3,024円
【タイトル】特集 肝胆膵がん治療2016
 企画:古瀬純司
・肝細胞がんに対する切除手術の動向北口和彦/後藤田直人
・肝細胞がんの局所療法:RFA&TACE-最近の進歩鈴木英一郎
・肝細胞がんの薬物療法-分子標的治療と肝動注のエビデンス上嶋一臣
・肝細胞がんに対する放射線治療の位置付けと最近の動向藤  浩
・胆管がんに対する切除と術後補助化学療法の動向駒屋憲一/江畑智希/水野隆史/梛野正人
・切除不能胆道がんの薬物療法-新たなバイオマーカーと最近の動向池田公史
・膵癌切除の進歩と補助療法元井冬彦/水間正道/林 洋毅/海野倫明
・切除不能膵がんの化学療法-一次治療をどうするか石井 浩
・膵がん二次治療のエビデンスと最新情報岡野尚弘/河合桐男/成毛大輔/長島文夫/古瀬純司
・膵がんにおける放射線治療の位置付けと最近の動向伊藤芳紀
・家族性膵がんの臨床的意義森実千種
・膵神経内分泌腫瘍の切除手術と薬物療法-適切な治療選択工藤 篤/伴 大輔/田中真二/田邉 稔
・膵神経内分泌腫瘍・がんの薬物療法~どう使い分けるか~肱岡 範/渋谷 仁/水野伸匡/原 和生
関連記事


コメント
コメントの投稿


管理者にだけ表示を許可する

トラックバック
http://paxxmedia.blog38.fc2.com/tb.php/9034-5e7e7bf8
この記事にトラックバックする(FC2ブログユーザー)


上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。